Zymeworks Inc. (ZYME) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $27.54: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 10.00; Below-average business quality; Negative price momentum.
Zymeworks is a biotechnology company pursuing a royalty-driven asset aggregation strategy, with zanidatamab (Ziihera) approved for HER2+ biliary tract cancer and licensed to Jazz Pharmaceuticals and BeOne Medicines. Revenue comes from royalties and milestone payments; the... Read more
Sell if holding. Engine safety override at $27.54: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 10.00; Below-average business quality; Negative price momentum. Chart setup: RSI 59 mid-range, Bollinger mid-band. Score 5.1/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerJazz, BeOne and J&J10-K Item 1A: 'We depend on our collaborative relationships with Jazz, BeOne and J&J to further develop and commercialize zanidatamab'
Material Events(8-K, last 90d)
- 2026-04-01Item 5.02LOWKristin Stafford appointed EVP and CFO effective April 1, 2026. Previously SVP/Chief Accounting Officer at Royalty Pharma plc. Clean handoff; no disagreement cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -76.6%. Quality floor flags this regardless of sector context.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $27.54: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 10.00; Below-average business quality; Negative price momentum. Chart setup: RSI 59 mid-range, Bollinger mid-band. Prior stop was $25.60. Score 5.1/10, moderate confidence.
Take-profit target: $34.87 (+26.7% upside). Prior stop was $25.60. Stop-loss: $25.60.
Concentration risk — Customer: Jazz, BeOne and J&J; Quality below floor (2.2 < 4.0); Value-trap signals (2/5): Revenue declining (-8.2% YoY), High leverage (D/E 3.8).
Zymeworks Inc. trades at a P/E of N/A (forward 35.4). TrendMatrix value score: 4.4/10. Verdict: Sell.
20 analysts cover ZYME with a consensus score of 4.3/5. Average price target: $40.
What does Zymeworks Inc. do?Zymeworks is a biotechnology company pursuing a royalty-driven asset aggregation strategy, with zanidatamab (Ziihera)...
Zymeworks is a biotechnology company pursuing a royalty-driven asset aggregation strategy, with zanidatamab (Ziihera) approved for HER2+ biliary tract cancer and licensed to Jazz Pharmaceuticals and BeOne Medicines. Revenue comes from royalties and milestone payments; the company has incurred losses since inception and expects continued losses.